Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "IMI"

4714 News Found

Dr. Bharti Pawar to participate in Global Conference on Antimicrobial Resistance
News | November 24, 2022

Dr. Bharti Pawar to participate in Global Conference on Antimicrobial Resistance

The conference is also expected to pave the way for nations to come out with bold and specific political commitments in the 2024 UN General Assembly High-Level Meeting on AMR


Dr. Lucica Ditiu appreciates India's TB elimination response
Policy | November 11, 2022

Dr. Lucica Ditiu appreciates India's TB elimination response

Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi


Cipla receives US FDA approval for Revlimid (Lenalidomide) capsules
Drug Approval | September 08, 2022

Cipla receives US FDA approval for Revlimid (Lenalidomide) capsules

Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings


Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines
News | September 07, 2022

Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines

Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.


Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab
Clinical Trials | August 20, 2022

Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets


Briefs: Zydus Lifesciences and Kimia Biosciences
News | August 09, 2022

Briefs: Zydus Lifesciences and Kimia Biosciences

The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.


FDC Limited reports Q1 FY23 revenue growth of 10%
News | August 08, 2022

FDC Limited reports Q1 FY23 revenue growth of 10%

The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands


Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey
News | July 26, 2022

Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey

72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey